米托蒽醌为主的联合化疗治疗急性髓细胞性白血病126例疗效分析

目的 评估以米托蒽醌为主的联合化疗方案,治疗成人急性髓细胞性白血病的疗效。方法 对本所１９９３年１月－１９９７的１２月住院的成人急性髓细胞性白血病患者,采用以米托蒽醌为主的联合化疗方案进行治疗,共１２６例。其中初治８５例,难治复发５１例。结果实治组与复发难治组的完全缓解率分别为４４．７％,２７．５％;部分缓解率２０．０％,９．８％。

A study of mitoxantrone with other chemical agents in treating 126 cases of adult acute myeloid leukemia

Objective To estimate the effect of mitoxantrone with other chemical agents in treating adult acute myeloid leukemia. Methods 126 inpatients diagnosed as acute myeloid leukemia between January 1993 to December 1997 were treated with mitoxantrone with other chemical agents . 85 had not been treated previously, (untreated ) while 51 were relapsing or resistant to previous treatment. Results The complete response rate among untreated and the relapsing / resistant groups were 44.7% and 27.5% ; while the partial response rate were 20.0%, 9.8% respectively. 4 patients were in the untreated group died early .The main sideeffect of mitoxantrone is bone marrow depression which led to fever and bleeding with rates of 40.4%, 24.3%. The nonbone marrow sideeffects were tolerable. Damage to the liver was a prominent occurrence 31.8%. Conclusion mitoxantrone was effective as the first line antitumor drug with other chemical agents in treating adult acute myeloid leukemia, its sideeffects were mild .